A Phase II, Open-Label, Multicenter, Pilot Study of the Safety and Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer.

Trial Profile

A Phase II, Open-Label, Multicenter, Pilot Study of the Safety and Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2012

At a glance

  • Drugs Bevacizumab; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Trastuzumab
  • Indications Breast cancer; Early breast cancer
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 04 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Planned number of patients (150) added as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Planned end date changed from 1 Dec 2009 to 1 Aug 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top